Overview

A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sling Therapeutics, Inc.